Targeted therapies for renal cell carcinoma: understanding their impact on survival
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11523-010-0145-6.pdf
Reference43 articles.
1. Paget S (1889) The distribution of secondary growth in cancer of the breast. Lancet 133(3421):571–573
2. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289–296. doi: 10.1200/jco.20.1.289
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590. doi: 10.1200/jco.2008.20.1293
4. Escudier BJ, Bellmunt J, Negrier S, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, on behalf of the AVOREN Investigators (2009) Final results of the phase iii, randomized, double-blind AVOREN trial of first-line bevacizumab (bev) + interferon-{alpha}2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 27(15S):5020
5. Rini BI, Halabi S, Rosenberg J, Stadler WM, Vaena DA, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2009) Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for calgb 90206. J Clin Oncol (Meeting Abstracts) 27(18S):LBA5019-
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Renal cell cancer with solitary gastric metastasis: a rare presentation;BMJ Case Reports;2021-06
2. Melatonin‐triggered post‐transcriptional and post‐translational modifications of ADAMTS1 coordinately retard tumorigenesis and metastasis of renal cell carcinoma;Journal of Pineal Research;2020-06-05
3. Exploring serum metabolic markers for the discrimination of ccRCC from renal angiomyolipoma by metabolomics;Biomarkers in Medicine;2020-06
4. LncRNA, NEAT1 is a prognosis biomarker and regulates cancer progression via epithelial-mesenchymal transition in clear cell renal cell carcinoma;Cancer Biomarkers;2017-05-06
5. Metastasis in renal cell carcinoma: Biology and implications for therapy;Asian Journal of Urology;2016-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3